ACRS Aclaris Therapeutics, Inc.: institutional ownership and insider trading
157 funds reported holding $659M of Aclaris Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $54.5M, with 27 new positions and 14 funds selling out; over the last 12 months insiders bought $0 and sold $1.36M on the open market.
Famous investors holding ACRS
- Renaissance Technologies (Renaissance Technologies): $4.32M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $12.6M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $2.77M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $2.19M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $704K, 0.0% of the portfolio
Largest institutional holders of ACRS
- RA CAPITAL MANAGEMENT, L.P. — $67.3M
- BML Capital Management, LLC — $63.3M
- BlackRock, Inc. (BLK) — $53.1M
- Deep Track Capital, LP — $49.4M
- Vivo Capital, LLC — $35.4M
- VANGUARD CAPITAL MANAGEMENT LLC — $30.8M
- Frazier Life Sciences Management, L.P. — $26.1M
- Rock Springs Capital Management LP — $22.9M
- ADAGE CAPITAL PARTNERS GP, L.L.C. — $21.5M
- Decheng Capital LLC — $21.4M
Recent ACRS insider trades
- Apr 23, 2026: Leonard Braden Michael sold 300,000 shares ($1.36M)
- Nov 19, 2024: Mehra Anand bought 666,666 shares ($1.50M)
5%+ owners
- BML Investment Partners, L.P.: 9.9% (Schedule 13G/A, filed Apr 27, 2026)
- RA Capital Management, L.P.: 9.1% (Schedule 13G/A, filed Aug 14, 2026)
- Deep Track Capital, LP: 7.0% (Schedule 13G, filed Mar 17, 2026)
- Frazier Life Sciences Public Fund, L.P.: 5.4% (Schedule 13G, filed Sep 21, 2026)